BCAL Diagnostics (ASX:BDX) Accumulated Depreciation: A$-2.21 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is BCAL Diagnostics Accumulated Depreciation?

BCAL Diagnostics ASX:BDX -1.32% Accumulated Depreciation is A$-2.21 Mil as of Jun. 2026. The stock has 5 warning signs investors should review.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

BCAL Diagnostics's quarterly accumulated depreciation declined from Jun. 2025 (A$-1.71 Mil) to Dec. 2025 (A$0.00 Mil) but then increased from Dec. 2025 (A$0.00 Mil) to Jun. 2026 (A$-2.21 Mil).

BCAL Diagnostics's annual accumulated depreciation increased from Jun. 2024 (A$-0.71 Mil) to Jun. 2025 (A$-1.71 Mil) and increased from Jun. 2025 (A$-1.71 Mil) to Jun. 2026 (A$-2.21 Mil).

BCAL Diagnostics Accumulated Depreciation Related Terms

BCAL Diagnostics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for BCAL Diagnostics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics Accumulated Depreciation Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25 Jun26
Accumulated Depreciation
-0.05 -0.13 -0.71 -1.71 -2.21

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.71 0.00 -1.71 0.00 -2.21

BCAL Diagnostics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of A$-2.21 Mil mean?
BCAL Diagnostics (ASX:BDX) has a Accumulated Depreciation of A$-2.21 Mil as of Jun. 2026. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on BCAL Diagnostics and its competitors.
Is BCAL Diagnostics' Accumulated Depreciation too high?
BCAL Diagnostics' current Accumulated Depreciation is A$-2.21 Mil.
How does BCAL Diagnostics' Accumulated Depreciation compare to TMO and DHR?
BCAL Diagnostics' Accumulated Depreciation of A$-2.21 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Medical Diagnostics & Research company?
A good Accumulated Depreciation depends on the Medical Diagnostics & Research industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on BCAL Diagnostics and its competitors. BCAL Diagnostics's current Accumulated Depreciation is A$-2.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BCAL Diagnostics stock overvalued right now?
BCAL Diagnostics (ASX:BDX) has a current Accumulated Depreciation of A$-2.21 Mil. The current Accumulated Depreciation is A$-2.21 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For BCAL Diagnostics (ASX:BDX), the current Accumulated Depreciation is A$-2.21 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BCAL Diagnostics Business Description

Address 50 Clarence Street, Suite 506, Level 5, Sydney, NSW, AUS, 2000
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost-effective, accurate, and available to all women regardless of age, race, and geographic location.